LBA1Fast progression in patients treated with a checkpoint inhibitor (cpi) vs chemotherapy in OAK, a phase III trial of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC
Gandara, D R, Reck, M, Morris, S, Cardona, A, Mendus, D, Ballinger, M, Rittmeyer, AVolume:
29
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdy511
Date:
December, 2018
File:
PDF, 101 KB
english, 2018